Sign In
Buy CRMD
$8.23
+0.0600 (+0.734%)
At Close: Jun 03, 2026
CorMedix (CRMD) Upgraded to Strong Buy: What Does It Mean for the Stock?
01:01pm, Friday, 08'th Nov 2024
CorMedix (CRMD) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Best Momentum Stocks to Buy for November 8th
11:15am, Friday, 08'th Nov 2024
CRMD, FFIC and SPPJY made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on November 8, 2024.
Stock Picks From Seeking Alpha's October 2024 New Analysts
08:00am, Friday, 08'th Nov 2024
In October, 42 new analysts joined Seeking Alpha, sharing diverse investment ideas and strategies, from biotech to real estate. Highlighted strong buy recommendations include MicroStrategy, CorMedix,
New Strong Buy Stocks for November 8th
07:16am, Friday, 08'th Nov 2024
SPPJY, FFIC, CRMD, NTGR and AACAY have been added to the Zacks Rank #1 (Strong Buy) List on November 8, 2024.
Wall Street Analysts See a 52.15% Upside in CorMedix (CRMD): Can the Stock Really Move This High?
10:55am, Monday, 04'th Nov 2024
The consensus price target hints at a 52.2% upside potential for CorMedix (CRMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate
CorMedix Inc. to Participate in the Truist Securities BioPharma Symposium
08:30am, Monday, 04'th Nov 2024
BERKELEY HEIGHTS, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening
CorMedix Inc. (CRMD) Q3 2024 Earnings Call Transcript
12:32pm, Wednesday, 30'th Oct 2024
CorMedix Inc. (NASDAQ:CRMD ) Q3 2024 Earnings Call October 30, 2024 8:30 AM ET Company Participants Dan Ferry - Investor Relations Joe Todisco - Chief Executive Officer Matt David - Executive Vice Pre
CorMedix (CRMD) Reports Q3 Loss, Tops Revenue Estimates
09:40am, Wednesday, 30'th Oct 2024
CorMedix (CRMD) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.17 per share a year ago.
CorMedix Inc. Reports Third Quarter and Nine Month 2024 Financial Results and Provides Business Update
07:30am, Wednesday, 30'th Oct 2024
‒ Q3 2024 Net Revenue of $11.5 million ‒ ‒ Commercializing DefenCath with Four of Top Five US Dialysis Providers ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ BERKELE
CorMedix 2.0: New Leadership, New Approval, New Focus
01:33pm, Monday, 28'th Oct 2024
CorMedix is a biopharmaceutical company that has undergone a re-birth as it enters a new phase with FDA approval of its anti-infective catheter solution, DefenCath. The company has faced challenges in
Undercovered Dozen: CorMedix, Cabaletta, Skyx Platforms, Dynex Capital +
02:30pm, Friday, 25'th Oct 2024
The 'Undercovered' Dozen highlights 12 lesser-covered stock ideas from October 18th - 24th, offering fresh investment takes for community discussion. Dnis Buivolov updates their Nebius Group valuation
CorMedix Inc. Announces New Data at ASN Kidney Week 2024
08:30am, Thursday, 24'th Oct 2024
Study highlights significant healthcare challenges and costs associated with bloodstream infections (BSIs) in patients receiving chronic hemodialysis through central venous catheters (HD-CVCs) Study h
CorMedix Inc. to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on October 30, 2024
08:30am, Wednesday, 23'rd Oct 2024
BERKELEY HEIGHTS, N.J., Oct. 23, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening
CorMedix Inc. to Present at the Cantor Global Healthcare Conference
08:30am, Friday, 13'th Sep 2024
BERKELEY HEIGHTS, N.J., Sept. 13, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention a
Here's Why CorMedix (CRMD) Is a Great 'Buy the Bottom' Stock Now
10:56am, Monday, 09'th Sep 2024
After losing some value lately, a hammer chart pattern has been formed for CorMedix (CRMD), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisi
